Patent ID: 7358222

Claim:
A pharmaceutical formulation for treatment of airway mucus hypersecretion, comprising: a) an epidermal growth factor receptor (EGF-R) antagonist that binds to an EGF-R in a therapeutically effective amount that is sufficient to reduce airway mucus hypersecretion, wherein said EGF-R antagonist is a tyrosine kinase inhibitor of the formula: wherein n is 1, 2 or 3 and each R 2 is independently halogeno or trifluoromethyl; R 3 is (1-4C)alkoxy; and R 1 is di-[(1-4C)alkyl]amino-(2-4C)alkoxy, pyrrolidin-1-yl-(2-4C)alkoxy, piperidino-(2-4C)alkoxy, morpholino-(2-4C)alkoxy, piperazin-1-yl-(2-4C)alkoxy, 4-(1-4C)alkylpiperazin-1-yl-(2-4C)alkoxy, imidazol-1-yl-(2-4C)alkoxy, di-[(1-4C)alkoxy-(2-4C)alkyl]amino-(2-4C)alkoxy, thiamorpholino-(2-4C)alkoxy, 1-oxothiamorpholino-(2-4C)alkoxy or 1,1-dioxothiamorpholino-(2-4C)alkoxy, and wherein any of the above-mentioned R 1 substituents comprising a CH 2 (methylene) group which is not attached to a N or O atom optionally bears on said CH 2 group a hydroxy substituent; or a pharmaceutically-acceptable salt thereof; b) a bronchodilator, a corticosteroid, an expectorant, or a mucolytic agent: and c) a flowable formulation suitable for delivery by inhalation.